Zhou et al. conducted a meta-analysis on fourteen studies (12,183 cases and 10,183 controls) and observed that RAD51 variant 135C homozygote is associated with an elevated risk of breast cancer among BRCA2 mutation carriers, but not in BRCA1 mutation carriers18. This evidence concerns the gene RAD51 and breast cancer.